H-D-Ala-OBzl·TosOH | H-D-Ala-OBzl.TosOH | Amines

CAS No. :	41036-32-2
Formula :	C₁₇H₂₁NO₅S
M.W :	351.42
SMILES Code :	O=S(C1=CC=C(C)C=C1)(O)=O.C[C@@H](N)C(OCC2=CC=CC=C2)=O
MDL No. :	MFCD00039092
InChI Key :	NWOPHJSSBMABBD-DDWIOCJRSA-N
Pubchem ID :	2802425

Safety of [ 41036-32-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 41036-32-2 ] Show Less

Physicochemical Properties

Num. heavy atoms	24
Num. arom. heavy atoms	12
Fraction Csp3	0.24
Num. rotatable bonds	5
Num. H-bond acceptors	6.0
Num. H-bond donors	2.0
Molar Refractivity	91.09
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	115.07 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	3.02
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	-0.14
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.25
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.26
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.37
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.95

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.97
Solubility	3.76 mg/ml ; 0.0107 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.82
Solubility	5.29 mg/ml ; 0.0151 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.57
Solubility	0.955 mg/ml ; 0.00272 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	No
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-8.54 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	3.1

Application In Synthesis of [ 41036-32-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 41036-32-2 ]

[ 41036-32-2 ] Synthesis Path-Downstream 1~54

1
[ 41036-32-2 ]
(S)-2-tert-Butoxycarbonylamino-heptanedioic acid 7-benzyl ester [ No CAS ]
[ 18814-51-2 ]

References: [1]Bulletin of the Chemical Society of Japan,1976,vol. 49,p. 533 - 539.

2
[ 3262-72-4 ]
[ 41036-32-2 ]
[ 92261-75-1 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 5 - 14.

3
[ 1676-90-0 ]
[ 41036-32-2 ]
[ 92398-55-5 ]

References: [1]Journal of Medicinal Chemistry,1984,vol. 27,p. 1663 - 1668.

4
[ 41036-32-2 ]
[ 70642-87-4 ]
[ 96523-76-1 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 647 - 655.

5
[ 41036-32-2 ]
[ 55878-47-2 ]
[ 96523-81-8 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 647 - 655.

6
[ 41036-32-2 ]
Boc-D-Arg(NO₂) [ No CAS ]
[ 92261-84-2 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 5 - 14.

7
[ 41036-32-2 ]
[ 65717-64-8 ]
[ 96523-69-2 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 647 - 655.

8
[ 41036-32-2 ]
[ 3401-36-3 ]
[ 132343-11-4 ]

References: [1]Bulletin de la Societe Chimique de France,1969,p. 2743 - 2747.

9
[ 41036-32-2 ]
[ 49827-15-8 ]
[ 171557-07-6 ]

References: [1]Journal of Organic Chemistry,1995,vol. 60,p. 6987 - 6997.

10
[ 41036-32-2 ]
C₉H₁₅BrO₄ [ No CAS ]
(2R)-2-(3-Bromo-2-methylpropionylamino)propionic acid benzyl ester [ No CAS ]

References: [1]Journal of the Chemical Society. Perkin transactions I,1998,p. 131 - 142.

12
[ 41036-32-2 ]
[ 100-52-7 ]
(R)-2-[1-Phenyl-meth-(E)-ylidene]-amino}-propionic acid benzyl ester [ No CAS ]

References: [1]Synlett,2000,p. 698 - 700.

13
[ 41036-32-2 ]
[ 186753-98-0 ]
[ 263010-60-2 ]

References: [1]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 32 - 40.

14
[ 5068-28-0 ]
[ 41036-32-2 ]
Boc-Cys(SBn)-D-Ala-OBn [ No CAS ]

References: [1]Monatshefte fur Chemie,2004,vol. 135,p. 979 - 999.

15
[ 1147-76-8 ]
[ 41036-32-2 ]
[ 736145-05-4 ]

References: [1]Il Farmaco,2004,vol. 59,p. 345 - 352.

16
[ 185990-56-1 ]
[ 41036-32-2 ]
[ 908589-92-4 ]

References: [1]European Journal of Organic Chemistry,2006,p. 2899 - 2911.

17
[ 27460-85-1 ]
[ 41036-32-2 ]
[ 947509-47-9 ]

References: [1]Journal of the American Chemical Society,2007,vol. 129,p. 8747 - 8755.

18
[ 41036-32-2 ]
[ 436848-62-3 ]
[ 947189-25-5 ]

References: [1]Journal of the American Chemical Society,2007,vol. 129,p. 8747 - 8755.

19
[ 69651-48-5 ]
[ 41036-32-2 ]
[ 947509-48-0 ]

References: [1]Journal of the American Chemical Society,2007,vol. 129,p. 8747 - 8755.

20
[ 41036-32-2 ]
(R)-2-[(Diphenyl-phosphinoyl)-phenyl-methyl]-amino}-propionic acid benzyl ester [ No CAS ]

References: [1]Synlett,2000,p. 698 - 700.

21
[ 41036-32-2 ]
[ 92261-95-5 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 5 - 14.

22
[ 41036-32-2 ]
[ 92261-77-3 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 5 - 14.

23
[ 41036-32-2 ]
[ 92261-81-9 ]

References: [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 5 - 14.

24
[ 41036-32-2 ]
[ 374756-15-7 ]

References: [1]Bulletin de la Societe Chimique de France,1969,p. 2743 - 2747.

25
[ 782493-67-8 ]
[ 41036-32-2 ]
C₃₃H₄₂F₃N₃O₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tris(acetoxy)borohydride; triethylamine; In 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran; at 20℃; for 168h;	EXAMPLE 76 Step A: D-alanine benzylester p-toluenesulfonic acid salt (22mg, 0. 062MMOL), triethylamine (9. 0muL, 0. 062MMOL), and sodium triacetoxyborohydride (22mg, 0. LOMMOL) were added to a stirring solution of 1-((1R,3S)-3-isopropyl-3-[6-(trifluoromethyl)-2H-1, 3-benzoxazin-3 (4H)- yl] carbonyl} cyclopentyl) piperidin-4-one (19MG, 0.021mmol) in DCM (LOML). The reaction mixture was stirred at rt for 96h, however, the reaction had not gone to completion. Another 39mg (0. 1 LMMOL) OF L- alanine BENZYLESTERP-TOLUENESULFONIC acid salt and 15, UL (0. 1 LMMOL) of triethylamine was added to the reaction mixture. After stirring for an additional 72h at rt, the reaction mixture was diluted with dichloromethane (50ML), washed with sodium bicarbonate solution (1 x 50ML) and brine (1 x 50ML), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by preparatory TLC (silica gel, 0. 25% ammonium hydroxide, 2.25% MeOH, 97.5% DCM) afforded the desired product. ESI-MS calculated for C33H42F3N304 : 601. 70, found 602 (M + H).
	With sodium tris(acetoxy)borohydride; triethylamine; In dichloromethane; at 20℃; for 168h;	Step A: D-alanine benzylester p-toluenesulfonic acid salt (22 mg, 0.062 mmol), triethylamine (9.0 muL, 0.062 mmol), and sodium triacetoxyborohydride (22 mg, 0.10 mmol) were added to a stirring solution of 1-((1R,3S)-3-isopropyl-3-[6-(trifluoromethyl)-2H-1,3-benzoxazin-3(4H)-yl]carbonyl}cyclopentyl)piperidin-4-one (19 mg, 0.021 mmol) in DCM (10 mL). The reaction mixture was stirred at rt for 96 h, however, the reaction had not gone to completion. Another 39 mg (0.11 mmol) of L-alanine benzylester p-toluenesulfonic acid salt and 15 muL (0.11 mmol) of triethylamine was added to the reaction mixture. After stirring for an additional 72 h at rt, the reaction mixture was diluted with dichloromethane (50 mL), washed with sodium bicarbonate solution (1×50 mL) and brine (1×50 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by preparatory TLC (silica gel, 0.25% ammonium hydroxide, 2.25% MeOH, 97.5% DCM) afforded the desired product. ESI-MS calculated for C33H42F3N3O4: 601.70. found 602 (M+H).

References: [1]Patent: WO2004/92124,2004,A2 .Location in patent: Page 113.
[2]Patent: US2007/238723,2007,A1 .Location in patent: Page/Page column 61.

26
dibenzylphosphoryl-L-alanyl-L-proline [ No CAS ]
[ 41036-32-2 ]
dibenzylphosphoryl-L-alanyl-L-prolyl-D-alanine benzylester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With benzotriazol-1-ol; In ethyl acetate; N,N-dimethyl-formamide;	Example 14 Dibenzylphosphoryl-L-alanyl-L-prolyl-D-alanine L-arginine salt: Dibenzylphosphoryl-L-alanyl-L-proline (1.4 g, 3.2 m mole), HOBt (476 mg, 3.5 m mole) and D-alanine benzylester p-toluene sulfonic acid salt (1.3 g, 3.5 m mole) were dissolved in DMF (5 ml), and WSC (0.64 ml) was added thereto while cooling to -15 C. The reaction was carried out for 3 hours under cooling and then overnight at room temperature. To the reaction solution ethyl acetate (100 ml) was added and the mixture was washed with 1N hydrochloric acid, 5% sodium bicarbonate and water in order. The mixture was dried with anhydrous sodium sulfate and the thus obtained solution was distilled under reduced pressure to give an oily dibenzylphosphoryl-L-alanyl-L-prolyl-D-alanine benzylester material.
	With benzotriazol-1-ol; In ethyl acetate; N,N-dimethyl-formamide;	EXAMPLE 14 Dibenzylphosphoryl-L-alanyl-L-prolyl-D-alanine L-arginine salt: Dibenzylphosphoryl-L-alanyl-L-proline (1.4 g, 3.2 m mole), HOBt (476 mg, 3.5 m mole) and D-alanine benzylester p-toluene sulfonic acid salt (1.3 g, 3.5 m mole) were dissolved in DMF (5 ml), and WSC (0.64 ml) was added thereto while cooling to -15 C. The reaction was carried out for 3 hours under cooling and then overnight at room temperature. To the reaction solution ethyl acetate (100 ml) was added and the mixture was washed with 1N hydrochloric acid, 5% sodium bicarbonate and water in order. The mixture was dried with anhydrous sodium sulfate and the solvent was distilled off under reduced, pressure to give oily dibenzylphosphoryl-L-alanyl-L-prolyl-D-alanine benzylester.

References: [1]Patent: US4472381,1984,A .
[2]Patent: US4536395,1985,A .

27
[ 926309-49-1 ]
[ 41036-32-2 ]
(R)-2-[(2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]-hydroxy-phosphorylamino}-propionic acid benzyl ester ammonium salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
7%	With dicyclohexyl-carbodiimide; In water; tert-butyl alcohol;	EXAMPLE 6 General Procedure monobasic Salts The appropriate amino acid ester (7 mol equivalent) was added to a solution of the nucleoside 5'-monophosphate species (1 mol equivalent) and DCC (5 mol. equivalent) in tert-BuOH (5 mL) and H2O (2 mL) and the resulting mixture was stirred and heated at reflux for 4 h. The solvent was removed in vacuo to afford the desired salt which was purified as described. ; step 2-azido-cytidine 5'-O-(benzyloxy-D-alaninyl)phosphate The title compound was prepared as described in Example 5 utilizing azido-cytidine monophosphate (100 mg, 0.294 mmol), <strong>[41036-32-2]D-alanine benzyl ester tosylate</strong> salt (14m 368.83 mg, 2.058 mmol), DCC (302.82 mg, 1.47 mmol) in tert-BuOH (5 mL) and H2O. The crude was purified by column chromatography eluting with a gradient starting from iso-PrOH, to iso-PrOH/conc. NH4OH/H2O (90:7:3, 85:10:5 and 80:12:8) to I-68 afford a white solid (7.8 mg, 0.0139 mmol, 7%). 31P NMR (D2O): delta6.52; 1H NMR (D2O): delta7.63 (1H, d, H6-cytidine, J=7.8 Hz), 7.25 (5H, CH-benzyl), 5.91 (1H, d, H1'-cytidine, J=3.0 Hz), 5.86 (1H, d, H5-cytidine, J=7.8 Hz), 5.00 (2H, s, CH2-benzyl), 4.25-4.13 (2H, m, H2'-cytidine, H3'-cytidine), 3.84 (2H, m, CH2 (2H, m, H5'-cytidine), 3.71 (1H, m, CHalpha), 1.37 (3H, d, CH3-lateral chain); MS (ES) m/e: 524.0 (M-, 100%); Accurate mass: C19H23N7O9P required 524.1295 found 524.1295.

References: [1]Patent: US2007/42988,2007,A1 .Location in patent: Page/Page column 19; 43.

28
[ 41036-32-2 ]
[ 770-12-7 ]
phenyl (benzyloxy-D-alaninyl)phosphorochloridate [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 5520 - 5530.

29
[ 41036-32-2 ]
[ 6622-55-5 ]
[ 1214259-11-6 ]

References: [1]Heterocycles,2010,vol. 81,p. 91 - 115.

30
[ 1708-29-8 ]
[ 41036-32-2 ]
[ 1257236-54-6 ]

Yield	Reaction Conditions	Operation in experiment
78%		Ozone gas was passed into a mixture of 2,5-dihydrofuran (1.994 g, 28.46 mmol), methanol (24 ml_),DCM (100 mL) at -60C,(containing a trace of sudan red), until the red colour disappeared leaving a greyish solution. After removal of excess ozone with nitrogen, sodium cyanotrihydroborate (1.252 g, 19.92 mmol) was added to the solution and the mixture stirred at -500C for 10mins. A solution benzyl (2R)-2-aminopropanoate p-toluenesulfonate salt (5 g, 14.23 mmol) in methanol (10OmL) was added dropwise and the stirring continued at 00C overnight. Acetic acid (0.815 mL, 14.23 mmol) was added and the mixture evaporated. The residue was dissolved in DCM (20OmL) and washed with saturated aqueous NaHCO3 solution. The organic extracts were dried over Na2SO4, filtered and evaporated to an oil. The crude product was purified by flash silica chromatography, elution gradient 15 to 50% EtOAc in isohexane. Pure fractions were evaporated to dryness to afford benzyl (2R)-2-morpholin- 4-ylpropanoate (2.75 g, 78 %) as a orange oil; m/z: 250.17 (MH+).

References: [1]Patent: WO2010/136778,2010,A1 .Location in patent: Page/Page column 56.

31
[ 1292320-84-3 ]
[ 41036-32-2 ]
[ 1292320-87-6 ]

Yield	Reaction Conditions	Operation in experiment
51%	With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 24h;	III. Dipeptides for absolute configuration determination and alpha/gamma-peptide studies.A number of alpha/gamma-dipeptides were prepared using Fmoc-AMCP and standard coupling reagents. However, all proved recalcitrant to crystallization from a wide range of solvent mixtures via slow evaporation. Boc-AMCP was therefore obtained and dipeptides using either D or L forms of Alanine benzyl ester tosylate were prepared (Scheme 5-3). Scheme 5-3. (a) Coupling of Boc-AMCP to LAla-OBn tosylate; (b) Coupling of Boc-AMCP to DAla-OBn tosylate.BocNH-AMCP-DAla-OBnThe couplings proceeded in moderate yields to provide useful amounts of both dipeptides. The dipeptides were isolated and several crystallization trials were set up using slow evaporation from mixtures of chloroform, ethyl acetate, methanol, heptane, and pentane. A mixture of ethyl acetate and heptane yielded large needles for the Boc-NH-AMCP-DAla-OBn dipeptide. These diffracted into the space group PI and the X-ray crystal structure was solved. The absolute configuration of the AMCP residue was shown to be (R,R) for the ring stereocenters, resulting from the Michael addition using the (S) catalyst. The relative configuration of the stereocenters is trans.

References: [1]Patent: WO2011/47190,2011,A1 .Location in patent: Page/Page column 63-64.
[2]Journal of Organic Chemistry,2013,vol. 78,p. 12351 - 12361.

32
[ 15761-38-3 ]
[ 41036-32-2 ]
N-t-butoxycarbonyl-L-alanyl-D-alanine benzyl ester [ No CAS ]

References: [1]Journal of the American Chemical Society,2012,vol. 134,p. 6120 - 6123.

33
[ 41036-32-2 ]
L-alanyl-D-alanine benzyl ester hydrochloride [ No CAS ]

References: [1]Journal of the American Chemical Society,2012,vol. 134,p. 6120 - 6123.

34
[ 41036-32-2 ]
C₂₄H₃₆N₄O₇ [ No CAS ]

References: [1]Journal of the American Chemical Society,2012,vol. 134,p. 6120 - 6123.

35
C₂₀H₃₁N₅O₈ [ No CAS ]
[ 41036-32-2 ]
[ 1428244-75-0 ]

References: [1]Journal of the American Chemical Society,2013,vol. 135,p. 4950 - 4953.

36
[ 352356-38-8 ]
[ 41036-32-2 ]
Boc-ACHC-DAla-OBn [ No CAS ]

References: [1]Angewandte Chemie - International Edition,2013,vol. 52,p. 12564 - 12567.
Angew. Chem.,2013,vol. 125,p. 12796 - 12799.

37
[ 41036-32-2 ]
C₁₇H₂₄N₂O₃ [ No CAS ]

References: [1]Angewandte Chemie - International Edition,2013,vol. 52,p. 12564 - 12567.
Angew. Chem.,2013,vol. 125,p. 12796 - 12799.

38
[ 41036-32-2 ]
Boc-ACHC-DAla-ACHC-DAla-OBn [ No CAS ]

References: [1]Angewandte Chemie - International Edition,2013,vol. 52,p. 12564 - 12567.
Angew. Chem.,2013,vol. 125,p. 12796 - 12799.

39
[ 41036-32-2 ]
Boc-DAla-(1R, 2S)-ACHC-DAla-(1R, 2S)-ACHC-DAla-OBn [ No CAS ]

References: [1]Angewandte Chemie - International Edition,2013,vol. 52,p. 12564 - 12567.
Angew. Chem.,2013,vol. 125,p. 12796 - 12799.

40
[ 53267-93-9 ]
[ 41036-32-2 ]
C₂₅H₃₂N₂O₆ [ No CAS ]

References: [1]Chemical Communications,2014,vol. 50,p. 3100 - 3102.

41
[ 41036-32-2 ]
C₂₀H₂₄N₂O₄ [ No CAS ]

References: [1]Chemical Communications,2014,vol. 50,p. 3100 - 3102.

42
[ 41036-32-2 ]
C₂₂H₂₆N₂O₅ [ No CAS ]

References: [1]Chemical Communications,2014,vol. 50,p. 3100 - 3102.

43
[ 41036-32-2 ]
[ 55721-65-8 ]
Boc-D-Ile-D-Ala-OBn [ No CAS ]

References: [1]Journal of Natural Products,2017,vol. 80,p. 2677 - 2683.

44
[ 13139-16-7 ]
[ 41036-32-2 ]
Boc-L-Ile-D-Ala-OBn [ No CAS ]

References: [1]Journal of Natural Products,2017,vol. 80,p. 2677 - 2683.

45
[ 338-69-2 ]
[ 104-15-4 ]
[ 100-51-6 ]
[ 41036-32-2 ]

References: [1]Journal of Natural Products,2017,vol. 80,p. 2677 - 2683.

46
[ 20312-37-2 ]
[ 41036-32-2 ]
C₁₆H₂₃NO₄ [ No CAS ]